Why Is OCULAR THERAPEUTIX I (OCUL) Stock Down Today?

Ocular Therapeutix shares fell 5.91% to $6.21 on Monday. The decline followed the release of third-quarter financial results that missed consensus estimates for both earnings and revenue. The company also announced a board change, electing Riad Sherif, M.D., to the board effective immediately.

What Happened

The primary driver for the sell-off was the company's Q3 performance. Ocular Therapeutix reported GAAP EPS of negative $0.42, missing the consensus estimate of negative $0.35 by $0.06. Revenue came in at $12.88 million, falling short of the expected $14.3 million by $1.42 million. Management noted that costs rose ahead of a potential launch for AXPAXLI in wet age-related macular degeneration. The company filed an 8-K with the SEC on November 9, 2026, to disclose these results. In a separate corporate action, the company elected Riad Sherif to its board, while another director resigned.

What The Data Shows

The stock printed three fresh 52-week lows on November 9. The 52-week range for the ticker is $6.00 to $16.44. Over the last eight sessions, the stock has declined 9.5%, moving from $7.29 to $6.59 before the latest drop. The company remains unprofitable with a trailing twelve-month EPS of negative $1.41, and revenue has decreased 8.1% over the same period. The market cap stands at $1.4 billion. Intraday, the stock opened at $6.59, hit a session high of $6.70 at 7:30 AM ET, and reached a low of $5.92 at 7:00 AM ET. Volume was 0.5 million shares, which is 0.2 times the three-month daily average. Recent insider activity includes six sales totaling $420,000 in the last 90 days, with no buys recorded.

What To Watch

Investors will monitor the company's progress on the NDA filing plans for AXPAXLI. The upcoming earnings call provides further context on the cost structure and launch timeline for the new product.